Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement or Other High Risk Features
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn about neoadjuvant cemiplimab with histology-specific chemotherapy followed by resection and adjuvant cemiplimab in stage 3 non-small cell lung cancer (NSCLC) with select N3 lymph node involvement or other high-risk subsets in which there is no consensus on resectability. The main question it aims to answer is whether patients with stage 3 NSCLC with involvement of lymph nodes can undergo surgery to remove the cancer after receiving treatment with chemotherapy + immunotherapy. Participants will receive FDA-approved chemotherapy called platinum-doublet chemotherapy together with an immunotherapy drug targeting the immune marker PD-1 called cemiplimab. Patients will receive a 3 drug combination for 4 total treatments given every 3 weeks before surgery. After surgery, patients will have the option to undergo radiation therapy if it is recommended by their treatment team. After this, they will receive cemiplimab every 3 weeks for one year.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rак płuca w stadium 3 z zajęciem węzłów chłonnych N3 lub inne cechy wysokiego ryzyka
- •Możliwość przeprowadzenia operacji - stan ogólny pacjenta pozwala na usunięcie nowotworu
- •Wystarczająca funkcja płuc do tolerowania planowanej operacji
- •Badania genetyczne wykazujące brak mutacji EGFR i ALK (poza formą płaskonabłonkową)
- •Dobra ogólna forma fizyczna (ocena ECOG 0-1)
- •Prawidłowe wyniki badań krwi i funkcji wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., United States
Washington University School of Medicine-Sitemen Cancer Center
St Louis, United States
UVA Comprehensive Cancer Center
Charlottesville, United States
Trial contact
Joshua Reuss, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.